Madrigal Pharmaceuticals, Inc. (MDGL) |
| 493.9 -16.63 (-3.26%) 01-13 16:00 |
| Open: | 511.57 |
| High: | 514.36 |
| Low: | 493.19 |
| Volume: | 430,259 |
| Market Cap: | 10,955(M) |
| PE Ratio: | -38.23 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 615.00 |
| Resistance 1: | 568.47 |
| Pivot price: | 569.23 |
| Support 1: | 493.19 |
| Support 2: | 410.33 |
| 52w High: | 615 |
| 52w Low: | 265 |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Financials
| EPS | -12.890 |
| Book Value | 27.560 |
| PEG Ratio | 0.00 |
| Gross Profit | 31.065 |
| Profit Margin (%) | -39.04 |
| Operating Margin (%) | -39.68 |
| Return on Assets (ttm) | -15.8 |
| Return on Equity (ttm) | -41.2 |
Company news
Mon, 12 Jan 2026
How Madrigal Pharmaceuticals Inc. (MDGL) Affects Rotational Strategy Timing - Stock Traders Daily
Mon, 12 Jan 2026
MDGL Secures Exclusive Global Right for MASH Treatment From PFE - Finviz
Sat, 10 Jan 2026
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Volatility And Long Term Momentum - Yahoo Finance
Sat, 10 Jan 2026
Madrigal Pharmaceuticals (MDGL) Is Down 13.4% After Pfizer MASH Deal And Wolfe Downgrade - What's Changed - Yahoo Finance
Fri, 09 Jan 2026
Madrigal Pharmaceuticals (MDGL) Secures Global License for Ervog - GuruFocus
Fri, 09 Jan 2026
Pfizer in pact with Madrigal for MASH drug (MDGL:NASDAQ) - Seeking Alpha
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
